Compare ANIP & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIP | SAM |
|---|---|---|
| Founded | 2001 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.6B |
| IPO Year | 1999 | 1996 |
| Metric | ANIP | SAM |
|---|---|---|
| Price | $76.28 | $231.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 9 |
| Target Price | $107.33 | ★ $229.50 |
| AVG Volume (30 Days) | ★ 298.2K | 142.2K |
| Earning Date | 05-11-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 419.23 | 95.45 |
| EPS | 3.32 | ★ 9.89 |
| Revenue | $206,547,000.00 | ★ $1,964,994,000.00 |
| Revenue This Year | $19.88 | $1.22 |
| Revenue Next Year | $15.77 | $1.46 |
| P/E Ratio | ★ $22.90 | $23.61 |
| Revenue Growth | ★ 2.47 | N/A |
| 52 Week Low | $56.71 | $186.72 |
| 52 Week High | $99.50 | $260.00 |
| Indicator | ANIP | SAM |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 54.18 |
| Support Level | $75.20 | $210.53 |
| Resistance Level | $84.47 | $249.47 |
| Average True Range (ATR) | 2.44 | 8.84 |
| MACD | 0.15 | -0.30 |
| Stochastic Oscillator | 61.39 | 76.83 |
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.